publication venue for
- When is an answer not an answer?. 10:189-190. 2013
- Registered clinical trials: first the bad news…. 9:353-354. 2012
- First move the goal posts, and then change the team: an evaluation of the EORTC intergroup study 30987. 9:263-264. 2012
- Moving up in the world: screening for lung cancer. 9:110-111. 2012
- Counting what really counts: the irinotecan in recurrent glioblastoma trial. 8:425-426. 2011
- Size, follow-up, data analysis—good; post hoc analysis, interpretation—not so much. 8:379-380. 2011
- On replicating studies, phase II and phase III trials, and other vagaries of clinical research. 8:141-142. 2011
- Measuring subjective phenomena. 8:43-45. 2011
- Causation. 7:573-575. 2010
- Observational studies. 7:520-522. 2010
- Survival analysis. 7:477-479. 2010
- Missing data. 7:429-431. 2010
- Binary dependent variables: logistic regression. 7:367-368. 2010
- Relations between continuous variables. 7:333-335. 2010
- Body counts and biostatistics: the chi-square test. 7:286-287. 2010
- Many groups, many factors: analysis of variance. 7:237-239. 2010
- Two for t: two groups and t-tests. 7:189-191. 2010
- Descriptive statistics and the normal curve. 7:141-144. 2010
- Mass screening: when does it make sense?. 7:93-95. 2010
- Measures of risk. 7:39-41. 2010
- Measures of disease frequency and mortality. 6:573-575. 2009
- Biases in randomized controlled trials. 6:527-529. 2009
- Efficacy and effectiveness trials. 6:472-474. 2009
- Diagnostic testing. 6:428-430. 2009
- Noninferiority trials. 6:380-382. 2009
- Power tripping: alpha errors, beta errors and power. 6:322-327. 2009
- P less than 0.05: statistical inference. 6:284-286. 2009
- Understanding meta-analysis. 6:232-235. 2009
- Data variables and distributions. 6:173-175. 2009
- Randomized controlled trials. 6:83-85. 2009
- Drug trial phases. 6:36-40. 2009
- How not to build a trial. 6:40-40. 2009
- Why we need statistics. 6:38-39. 2009